EP. 5: Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis
June 5th 2022
Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.